Besinger R E, Niebyl J R
Department of Obstetrics and Gynecology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois.
Obstet Gynecol Surv. 1990 Jul;45(7):415-40. doi: 10.1097/00006254-199007000-00002.
Pharmacologic inhibition of uterine contractions remains the mainstay of treatment for preterm labor despite the ongoing controversy regarding its effectiveness. A diverse variety of tocolytic medications have been proposed for clinical use, with betamimetics and magnesium sulfate being the common therapeutic agents of choice in the United States today. The clinician using these agents should be aware of the significant maternal and fetal side-effects associated with these particular medications. New classes of pharmacologic agents, including prostaglandin synthetase inhibitors, calcium channel blockers and phosphodiesterase inhibitors, have been proposed as tocolytic agents and are currently undergoing critical clinical evaluation. The purpose of this review is to provide a compilation of the available clinical studies that document the safety and efficacy of these various tocolytic agents.
尽管关于抑制宫缩药物的有效性仍存在争议，但药理学抑制子宫收缩仍是早产治疗的主要手段。已有多种宫缩抑制剂被提议用于临床，在美国，β-拟交感神经药和硫酸镁是目前常用的治疗药物。使用这些药物的临床医生应意识到这些特定药物会带来显著的母婴副作用。包括前列腺素合成酶抑制剂、钙通道阻滞剂和磷酸二酯酶抑制剂在内的新型药理学药物已被提议作为宫缩抑制剂，目前正在进行严格的临床评估。本综述的目的是汇编现有临床研究，记录这些不同宫缩抑制剂的安全性和有效性。
